Back to top

gene-editing: Archive

Sundeep Ganoria

BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?

Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects.

REGNNegative Net Change BEAMNegative Net Change NTLANegative Net Change

Zacks Equity Research

Sarepta's Stock Rises on Positive Updates on DM1 Therapy

SRPT's stock jumps as its SRP-1003 study advances with a positive safety review and new dosing cohorts underway.

SRPTNegative Net Change RNAPositive Net Change ARWRNegative Net Change PEPGNegative Net Change

Ekta Bagri

Top 3 Genomics Stocks to Consider for Your Portfolio

Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.

ILMNNegative Net Change PACBNegative Net Change EDITNegative Net Change NTLANegative Net Change CRSPNegative Net Change SANAPositive Net Change

Zacks Equity Research

FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings

SRPT's Elevidys gets a sharply narrowed FDA label with new liver safety warnings that reshape how the gene therapy can be used.

RHHBYPositive Net Change ALKSNegative Net Change SRPTNegative Net Change CRMDNegative Net Change